Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer

Summary

This is a single arm study to evaluate the efficacy and safety of CEA-targeted CAR-T cells therapy for patients with relapsed/refractory CEA+ Cancer,and obtain the recommended dose and infusion plan.

Timeline

Start

2020-02-20

Primary completion

2023-12-31

Completion

2024-04-30

Outcome

Outcome not reported

Stopped: “The sponsor requested to terminate the study.”

Drugs

Indications